Biocom Lifelines - Spring 2014

LifeLines For the Southern California Life Science Community

10

New Year Brings New Policy Challenges for Biocom

13

Ten Reasons You Should Attend an Event

22

Our 2014 New Year’s Resolutions

patients

more approach

venture

better

inspirational

genetic

dialog

medicine

drugs opportunity

international

amount

successful

close

healthcare

digital health

working

big lot way important

unique

event

jobs

high

data

little

company

provides

personalized

research

investors

consumers

drive

need

initial

based

annual

situation

many

life

begin

drive

open

critical

set

markets

2014 market large

effects

best think become even ideas start outcomes

make

partners

moving

February

field

premium

many

together saw window health trying passion

cost

going

conference

long next steady

significant moving

funds changes

disease

pharma insurance

population

years others

ahead

therapy

diagnostic

technologies

early competition

sequence

profile

term

low required

identify

planning

providing

right

value

deal

science San Diego life science

phase

benefits

innovation

example

stream

FDA

look

system

through

support

response

support

underway

year

develop

high

including

using

reduced

access feast

robust

medical

results

found

warranted

new

employees

creative

forward

good

real energy

funding

defined

research

office

quality

come available

capital clinical

much forces products

biotech individual

development

use find

sharing

tailored

rest

part still

molecular

Volume 23, Issue 1 S p r i n g 2 0 1 4

open

see over

first

price

treat

impact sector

pipeline

issues

take

stage

information

allows given

past space

many

business

time

precision

now

energy

government continue

one answer

ways

maintain

greater

close

help

trend

hope

world change non

pharmaceutical

seeing

costs

IPO care those

making

top remain

products

specific resources

life easy

pricing

largest

Genomatica has relied on the C&W Life Sciences team as its real estate advisor for years. Throughout our early years, C&W negotiated very flexible terms and rights. These same rights later allowed us the flexibility for an early exit and the ability to negotiate great pricing and terms for our new headquarters building. With their help, we secured a custom designed project which highlights our science and positions us for success. I highly recommend them to other life science companies.

Christophe Schilling, CEO, Genomatica, Inc.

SUCCESS STARTS WITH HIRING THE RIGHT REAL ESTATE REPRESENTATION From start-ups to large pharmaceutical companies, we have an unsurpassed level of experience in advising and negotiating the best possible terms for your next laboratory facility. For the past 30 years, we have focused our career on helping companies like yours, find and negotiate leases on facilities that enhance the human experience, foster collaboration and innovation, and help attract and retain the best and brightest talent.

Let us be your partner in success.

See what we can do for you: www.sdlifesciences.com

(858) 452-6500

BRENT JACOBS

GREG BISCONTI

TED JACOBS

CA LICENSE NO. 791657

CA LICENSE NO. 1167920

CA LICENSE NO. 1855220

WELCOME

I n T h is I ss u e

By Joe Panetta, President and CEO, Biocom

2 Cover Story: I see.... 2014 10 Public Policy : New Year Brings New Policy Challenges for Biocom

11 Members in Action: HR Conference, Breakfast Meeting

12 Members in Action: Annual Celebration of Life Dinner

13 Events: Ten Reasons You Should Attend an Event 16 Guest: San Diego Public Companies to Watch in 2014

18 The San Diego Festival of Science & Engineering - Be there!

20 Biocom Institute: Life Science Summer Institute Celebrates 10th Anniversary of Developing a Workforce Pipeline

22 Biocom Purchasing Group: Our 2014 New Year’s Resolutions

24 Premium Member Spotlights:

Fisher Scientific, GE Healthcare Life Sciences, Janssen Labs, Wilson Sonsini Goodrich & Rosati

27 Biocom Board and Committees 28 Biocom Membership

E d i to r : Jennifer Landress CO P Y E d i to r : Josh Baxt DESIGN & LAyout: Arlene Arreola V o l u m e 2 3 , I ss u e 1

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development. To learn more visit us at www.

Biocom.org

Good News

Welcome to our Spring 2014 edition of LifeLines. In this issue, we focus on expectations for 2014 from the perspectives of both the Biocom staff and the industry members we serve.

I am particularly encouraged after attending the annual JP Morgan Health Care Conference in January. The climate was more upbeat than ever regarding the future of the life science industry. The conference highlighted large pharma’s growing focus on developing biological products, as well as their significant advances in creating research tools and diagnostics—successes that will serve Southern California well. So, on this positive note, I know you’ll enjoy our cover story on predictions for 2014 as much as I did.

Biocom had a very successful 2013 on the advocacy front, opening our Washington D.C. office and leading the California life science community’s Sacramento public policy efforts with our partners BayBio and CHI. This year brings a new set of challenges, such as lobbying for increased NIH funding, ensuring a positive regulatory climate in California and working with our new San Diego mayor. These are discussed by our veteran vice president of Public Policy, Jimmy Jackson.

Biocom has always been known for our aggressive and timely schedule of networking events and conferences. As you will read, the kick-off for our year is the highly successful annual Global Partnering Conference. In this issue, we’ll share the top 10 reasons to attend our events and conferences throughout the year. These events are designed to appeal to every level of your organization.

One of my favorite yearly events is the San Diego Festival of Science & Engineering, during which our companies and research institutes provide an opportunity for people throughout our community to learn more about life science and engineering, with a special focus on students. On that note, Liisa Bozinovic, the new Executive Director for the Biocom Institute has an article on the celebration of the 10th anniversary of the Life Science Summer Institute, a program that has been very successful in providing internships in life science companies for our local high school and college students.

On the membership side, I’m pleased that Biocom enlisted 120 new members in 2013, bringing our total membership to almost 600 firms. You’ll get a sneak peek at the new concierge program Biocom has created for our members to ensure that we continue to inform them about the multi-faceted benefits of Biocom membership.

Finally, our regular columnist Mandy Jackson rounds out our theme of predictions for 2014 with an article on top companies to watch. Given the diversity and depth of the life science sector that we serve, it’s difficult, if not impossible, to forecast success, but I know that you’ll find these cutting edge companies and their technologies intriguing. We’ll follow their progress, along with you, as we work to accelerate your success.

www.Biocom.org

Biocom LifeLines Spring 2014

1

Cover Story

I See...2014

Southern California’s Life Science Leaders Give their Insight on what to expect in 2014

The mood on the ground at the JPMorgan Healthcare Conference held in San Francisco each January sets the tone for the industry for the year. This year, people were downright cheerful as they basked in the unseasonably warm sunshine in Union Square. While the year looks positive from an IPO perspective, the overall forecast remains cloudy, as our industry grapples with the looming changes of the Affordable Care Act and an uncertain payer environment. In light of this uncertain forecast, Biocom asked Southern California leaders about their outlook for 2014 and what big trends they see impacting our industry this year. In the following pages read what they had to say.

going flexibility much more extremely promising to see how science’s growing knowledge of genetics is beginning to have a meaningful and actionable impact on oncology

financing quality for

think there to

Strategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

oncology

in

see

be

with respect to “popular” indications, cancer therapeutics should continue to be front and center, with immunotherapies, especially antibody technologies, personalized medicine and stem cells also taking a leading role in the industry

promising science’s extremely

companies is

beginning It’s

actionable

and

Strategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

how

growing genetics

knowledge have This year partnering will become even more important and we’ll be seeing more deal structures that are creative and tailored to the situation

meaningful

impact

patients

more

e

s

successful

robust

medical

underway

using

close

system

healthcare

d

h

deal

including

high

jobs

data

Cover Story little

example

science San Diego life science sequence

company

provides

It will be challenging.

To justify premium pricing, biotechnology companies are all personalized trying to find differentiated drugs that have a significant impact planning in patients. These are not easy to come by, so naturally the drive competition is very intense, and you have to go further upstream stream Of the dominant disruptive forces to have access to quality innovations at a reasonable price. This phase profile research should result in more early-stage deal making in the years to come. consumers that are currently in play in healthcare,

open

critical

providing

right

identify

Magda Marquet, Ph.D. Founder and Co-chairman, Althea Technologies Executive Chair, Biocom Board of Directors

working

benefits

low required

event

investors

annual

drive

situation

many

begi

need

one of the most formidable is the trend Carin Canale initial towards individualized medicine using President, Canale Communications, tools such as pharmacogenomics. Although we have been talking Vice Chairwomen, Biocom Board of about it for over a decade and despite the fact that there are a few Directors make examples in oncology and cardiovascular disease, the main impact Open. Close. Open. Close? The back moving is still to come. With the staggering number of over 4 billion new and forth banter on the state of the IPO prescriptions written in 2012, the need to prescribe drugs using the window at the end of 2013, reminded me premium February pharmacogenetic profile of the patient could not be more pressing. of my daughter wanting the car window In the last couple of years the FDA itself has stepped in and listed open – her mind changes with the wind over 200 drugs with pharmacogenomics information on their every five seconds. As 2013 came to a diagnostic labels. There is little doubt that the impact of pharmacogenomics maintain close, while some predicted the end of the biotech IPO opportunity, on the elderly patient population will be profound. Consider I was steady with my forecast of an open and robust window for life these two facts: adverse drug reactions are among the top five science companies greatest threats to the health of seniors and on in 2014.

On average, seniors take 14 (ages 65 to 69) to 18 “what I predict is that there will be a steady the heels of the (ages 80significant to 84) prescriptions per year often drumbeat of IPOs and the best ideas – and only the annual JP Morgan concomitantly (seniors in nursing homes take conference, moving best ideas – for new medicines or other medic al on average 13 different prescriptions per day). it seems the By alerting the physician on a given patient’s sentiment is now innovations will be welcomed withinformation open arms.” or absorb a given drug, good hanges ability to metabolize quite unanimous — C arin C anale available pharmacogenomics will help millions avert life – the window will sector threatening and costly hospitalizations. remain open and

term

big

based

set

life

markets

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether passion window health trying saw technologies

unds

quality

ase

h

l

r

real energy

funding

defined

research

s

t

ahead

therapy

government continue

come

capital

sharing Diego Miralles, M.D. Global Head, Innovation, Janssen Pharmaceuticals

clinical

allows given

rest

office

products use find

part

precision past space

take

open

treat

impact

many stage

world change

help companies are standing in line to go public.

The question is how many and for how long? Nobody knows the answer, but what I predict is that there will be a steady drumbeatnon pharmaceutic of IPOs and the best ideas – and only the best ideas – for new seeing medicines or other medical innovations will be welcomed with open arms. What I don’t think we’ll see is the irrational exuberance of the genomics bubble, rather a market where the highs may not be as high, but the lows aren’t nearly as low. I those for one am not a fan of feast or famine. I think we’ve matured as an industry and my hope for 2014 is that the market will support only those companies with real data and real opportunity for value. products

over

first

one answer

pipeline

see

issues

right now based on the fact that the IPO window is open, valuations have gone up and investors are returning to the space.

Never has there been better science.

We are entering into therapeutic spaces and modalities that we never would have dreamed of. I really believe the possibilities are endless.

A big change is the impact of molecular diagnostic in cancer.

Like we have been long doing in infectious diseases, we can identify the ways drugs needed to treat that specific molecular change.

This results in reduced toxicity, better outcomes and price reduced unnecessary still costs. With a more rational use of drugs, we will have a better value proposition than we have in the past.

A big question is how quickly the system will evolve with regard to how we pay for healthcare. In the U.S. we are still able to obtain premium drug pricing that would be difficult to get anywhere else in the world. However, given the fiscal situation, how can the U.S. sustain that differential price relative to the rest of the world?

now

business

time

tailored There is a lot of energy in the industry

energy

greater

close

trend

hope

costs

IPO care

making

top remain

specific resources

life

Rich Heyman, Ph.D. President & CEO, Seragon pricing Pharmaceuticals I think for quality companies there largest is going to be much more flexibility in financing, and, as a CEO of a private company, my options are much greater than they were in the past.

Last year the strong companies went out at reasonable valuations and have increased in value over time. These companies have access to

Biocom LifeLines Spring 2014

3

easy

patients

more successful

robust

medical

deal

including underway

using Cover Story

low required

identify

event

high

jobs

data

little

example

San Diego life science “We are seeing greater patient engagement science healthcare and empowerment, and I think that trend close

system

sequence

working will continue through and beyond 2014.” stream — Hillary Theakston phase profile

benefits

right

open research

critical

providing

company

provides

begin

whistleblowers and issues under the Foreign Corrupt Practices Act (FCPA) and the Sunshine Act, for example, means that companies will needpersonalized to ensure they have strict risk and compliance programs annual planning in place to avoid serious chargesdrive and damaging allegations in the future.

consumers situation Executive Director, The Clearity Hillary Theakston

many

investors

need

drive

Foundation much more capital than they have in the last few years, putting initial them in an interesting position. Previously there were minimal We are seeing greater patient opportunities for an exit—only M&A. The IPOs offer a potential engagement and empowerment, liquidity event for investors and puts the management team in the make and I think that trend will continue moving or continue to go it alone because they position to either partner, through and beyond 2014. People are have enough capital to fund later stage programs. This is a great becoming more personally involved in February thing because with this business, which ispremium a hard business, you healthcare coverage decisions, now that want as much flexibility and optionality as possible. Because of the Affordable Care Act facilitates online access to insurance this, the mood in the industry is quite upbeat, and I don’t think information. Patients are flocking to online communities and using that the doors are going to slam shut any time soon. diagnostic social networks to obtain health information and to share their maintain However, a concern I have is that weaker companies may try to experiences to help others. Through traditional and social media, go public, and I hope that doesn’t spoil the market. It is important patients are learning about discoveries that may dramatically that public investors do enough homework to separate between the change treatment. We are shifting from a one-size-fits-all approach wheat and the chaff in a meaningful way. Another thing I get a little to more personalized one. This trend will converge with more worried about is whether the investors are going to begin investing significant empowered patients, who will not only demand improved health more in early stage companies again. It’s going to be important to outcomes, but better value for their healthcare dollar. moving have venture capital firms, both private and corporate, investing in early stage technologies or the pipeline will dry up.

Harry Gruber, M.D. President & CEO, Tocagen information good nges Lisa Haile, J.D., Ph.D. I believe that cancer immunotherapy available Partner, Co-Chair, Global Life Sciences will continue to make importantsector Sector, DLA Piper advances this year, and ultimately lead help Vice President & General Counsel, to a fundamental shift in the treatment sharing Biocom Board of Directors of cancer. This shift is reminiscent of non Following the annual JP Morgan pharmaceutical the dramatic progress against infectious defined Healthcare conference in San Francisco tailored disease after the introduction of vaccines.seeing the week of January 12, several trends While the invention of antibiotics was a for 2014 percolated to the top. First, huge leap forward in treating pathogens, infectious diseases were for the second year in a row, the mood only truly tamed with the advent of vaccines that elicit an immune those was upbeat and industry leaders appear optimistic for a successful response against the pathogen. In the same way, while small 2014. The IPO class of 2013 was one of the largest in biotech molecule drugs can be highly effective at killing cancer cells, the history with over 30 companies going public and 2014 should see most important way to treat cancer will be invigorating the immune the trend continue, assuming positive data and a low incidence products system to recognize and eliminate cancer cells. of clinical failures, which tend to rattle investors. Second, with Cancer immunotherapeutics is finally coming of age with the respect to “popular” indications, cancer therapeutics should approval of ipilimumab for treating melanoma, Science naming continue ways to be front and center, with immunotherapies, especially cancer immunotherapy as the “Breakthrough of the Year” for pricing antibody technologies, personalized medicine and stem cells also 2013, and the PD-1/PD-L1 targeting antibodies racing towards price taking a leading role in the industry. In addition, RNA technologies, largest approval. An additional technology involves CAR T cells, which uses still such as RNA interference (RNAi), should become more palatable gene therapy to reprogram patients’ T cells to target and destroy for investors in 2014, especially with the development of new lymphoma cells. Other companies, including Tocagen, are also and successful delivery systems which have been needed for this using gene therapy to harness the immune system to treat cancer. field to take off. Finally, compliance and transparency have been Our approach involves a tumor-selective retroviral replicating vector and will continue to be key issues for global companies in 2014. that delivers a therapeutic gene for an initial local antitumor effect The increase in internal and government investigations involving followed by a specific, systemic antitumor immune response. Our

term

big

based

set

life

markets

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether passion window health trying saw ahead

therapy

technologies

nds

quality

se

real energy

funding

research

come

capital clinical rest

office

products use find

4

part

Biocom LifeLines Spring 2014

government continue

allows given

take

open

treat

impact

over

first

one answer

pipeline

see

issues

past space

now many

business

time

precision

energy

greater

close

stage

trend

hope

world change

costs

IPO care

making

top remain

specific resources

life easy

more close

system

healthcare working

science San Diego life science sequence

company

provides

planning

personalized

Cover Story annual

drive

open

stream

lead product, Tocaphase 511, initially kills theprofile tumor by converting a prodrug into a potent anticancer agent within the cancer cell. providing These dying tumor cells then selectively stimulate the immune system to seek and destroy remaining cancer cells. This, and our other immunotherapy programs in development at our company in addition to alternative approaches at other companies, have the potential to become dramatically better tools in the fight against moving cancer.

begin

Standish Fleming consumers Managing Member and Owner, Forward many situation Ventures The IPO window will close. I know, initial that sounds like a no-brainer, but in some ways this window, the first under make the JOBS act, really has been different.

As skeptical as I am about Washington’s ability to do anything economically premium February constructive, they got this one right.

Damien McDevitt, Ph.D. VP & Head of BD for R&D Extended I’m not sure it has done anything for jobs, but JOBS has greatly Therapy Areas, Head of R&D West Coast improved the efficiency of the IPO process. The result has been a Satellite Office, Worldwide Business diagnostic better selection of companies, more accurate pricing and a more maintain Development, GlaxoSmithKline durable window. But, while JOBS improves the process, those The pharma industry has gotten a lot details do not drive the system. As the Fed takes away the freeof heat in recent years about its lack of money punch bowl, Wall Street will sober up and the window will R&D productivity and innovation and the close, gradually, I hope. drought of new medicines available to significant In 2014 we will begin to feel the full effects of Obama Care, and patients. That criticism, much of which they will not be good for biotech or innovation. Having fumbled movinghas led to a fair amount of soul searching about how, was warranted, the Affordable Care Act kick-off (the easy part), the political and with whom, we develop new medicines. The conclusion many establishment will now try to actually play the game (the hard part). of us have come to is that all of the available best science can’t The burden on the information Federal budget will result in a shift of national nges be foundgood within our company walls and that we must significantly healthcare priorities from investment (research) to consumption available increase access to external scientific and medical innovation to sector (services for 20-30 million additional enrollees). A thought for maintain a sustainable pipeline of novel medicines for patients. the paranoid: if the game doesn’t gohelp better than the kick-off, To do this, many large pharmas are joining forces with a broad sharing Obama Care might be the prelude to a single-payer system—a low range of scientists in academia, biotech, venture firms and even probability event but truly scary for biotech. non other pharma companies and we saw a lot of this activity in 2013. pharmaceutical defined This year partnering will become even more important and we’ll be seeing tailored “Working in creative ways with partners seeing more deal structures that are creative and tailored to the and constructively managing relationships situation.

A significant area of evolution is pharma’s relationship with will be critic al to developing the next those venture capital. Many pharmas, including GSK, have become generation of medicines for patients who limited partners in venture funds. Moving forward you will see even more creative pharma-VC relationships develop. GSK has are waiting.” established a unique discovery collaboration model with Avalon products — DAMIEN MCDEVITT Ventures to build up to 10 project-based companies together, sharing ideas and providing access to GSK technologies and Jay Lichter resources. ways pricing Managing Director, Avalon Ventures Working in creative ways with partners and constructively price largest Last year saw the opening of the managing relationships will be critical to developing the next still IPO window for the first time in years, generation of medicines for patients who are waiting. To do so it is and 2014 will continue to show strong critical to be where your partners are, which is why GSK set up a public market support for life science satellite office in San Diego in January 2014. companies. Additional IPO’s and followon financings will drive the broader market as newly public companies will look to expand their product offerings via licensing and M&A. The venture capital market will only slightly return in 2014. Strategic venture capital funds will continue to be the leading force in the industry, however, as liquidity is achieved via public markets, financial venture funds will make a comeback, late in the year and early in 2015.

benefits

right

critical

investors

term

big

research

based

set

drive

need

life

markets

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether saw window health trying passion ahead

therapy

technologies

nds

quality

se

real energy

funding

esearch

office

come

capital clinical

products use find

part

rest

government continue

allows given

take

open

treat

impact

over

first

one answer

pipeline

see

issues

past space

now many

business

time

precision

energy

greater

close

stage

trend

hope

world change

costs

IPO care

making

top remain

specific resources

life easy

Biocom LifeLines Spring 2014

5

patients

more successful

robust

medical

deal

including underway

using Cover Story

close

system

healthcare

low required

identify

event

high

jobs

data

science San Diego life science sequence

company

provides

The relationship between pharma and venture capital firms and venture-backed companies should remain on new more even personalized footing, because of the robust public markets. However, public “2014 will be the year that Connected planning markets can be fickle and change quickly. When this happens, turns the corner.” drive venture capital and biotech companies will need to be self-reliant stream — JACK FLORIO again. Hopefully, this won’t happen in 2014. phase profile

working

benefits

right

open research

critical

providing

little

example

Health

annual

consumers

drive

situation

many

begin

need

Steven Mento President & CEO, Conatus initial Pharmaceuticals disease, their own bodies and how to restore and maintain health.

What’s happened over the last decade Another driver is the change in the healthcare system that pushes is that large pharmaceutical companies makeof the cost and the decision-making responsibility onto the more movinghave increasingly looked to smaller consumer driving him or her to become more educated buyer and drug development companies for their concerned about maintaining their health to lower their costs. pipeline opportunities.

Fewer companies premium February We will start to see an even greater integration of the biotech and advance drugs all the way from concept pharmaceutical products of our Biocom members with the apps, to market independently. I think what technologies, and devices of the tech world working together with little companies do really well is focusing on trying to get it right diagnostic the focus on improving outcomes. maintain in the early stages. If they are successful with the preclinical and San Diego is in a unique position to establish itself as the clinical development of their products, they or their products often epicenter of this rapidly emerging market with the strength of are acquired by larger companies which then advance through organizations like Biocom, Qualcomm, WLSA, West Health, Scripps regulatory approval to commercialization. That’s neither good nor Translational Science Institute and too many others to mention bad, but does reflect the new reality in our industry. all working together with the common goal of demonstrating significant This new reality provides a tremendous opportunity for San leadership in how healthcare is delivered to the consumer and moving Diego. We have the entrepreneurial environment, infrastructure more importantly how health is maintained. and resources – excellent research institutions and universities, venture-backed funding, as well as good trade organizations and Mark Stevenson information good nges support networks – to facilitate the startup and growth of life Executive Vice President, Thermo Fisher available Scientific & President, Life Sciences sector sciences companies. What’s special about San Diego, however, is Solutions the sense of community. People are extremely supportive. We don’t help It’s extremely promising to see how look at other companies as competitors.

They’re part of the family sharing science’s growing knowledge of genetics of biotech in the San Diego region. I think that’s the reason we non is beginning to have a meaningful and pharmaceutical have so many companies positioning themselves in this industry defined actionable impact on oncology. Ourseeing in this location. tailored ability today to rapidly peer into the DNA of cancerous tumors through sequencing Jack Florio CEO, Amplyx Pharmaceuticals technology and accurately identify specific driver mutations with those 2014 will be the year that Connected the aid of cancer panels is changing how oncologists treat the Health turns the corner.

We will disease – at a very individualized level. But there is yet another begin to leave behind an environment evolving segment of the personalized medicine market that rivals with a collection of individual apps, products the growth we’ve seen in oncology, and which we have every reason technologies, and devices that populate to look forward to in the years ahead. consumers smart phones, computers, Pharmacogenomics (PGx) is poised to become a booming and phones. We are now moving into an business ways pricingthat also leverages genetics and sophisticated environment where all of this technology instruments, but with more immediate application. Currently, price on starts to become integrated into healthcare solutions focused there are about 70largest drugs on the market to treat conditions ranging improving still outcomes and lowering costs. This market will have from cardiovascular disease, depression and chronic pain, but how moved from a B2C market to a B2B2C market where the adoption can doctors discern which will work best for their patients? Similar will be driven by payors who will be demanding demonstrated to the revolution we’re seeing in oncology, PGx leverages genetics outcomes. to help doctors prescribe the right drug to the right patient. This One key driver of this is the democratization of health care where is great news for patients, who otherwise may be given a drug that consumers now possess a significant amount of information about isn’t compatible with their genetic makeup, but it’s also good for

investors

term

big

based

set

life

markets

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether passion window health trying saw ahead

therapy

technologies

nds

quality

se

real energy

funding

research

come

capital clinical rest

office

products use find

6

part

Biocom LifeLines Spring 2014

government continue

allows given

take

open

treat

impact

over

first

one answer

pipeline

see

issues

past space

now many

business

time

precision

energy

greater

close

stage

trend

hope

world change

costs

IPO care

making

top remain

specific resources

life easy

more close

system

healthcare working

science San Diego life science sequence

planning

right

critical

big

Cover Story annual

consumers The report notes situation that much of the health industry has accepted many

need

drive

that reform is here to stay – and forward-looking executives are

initial making decisions based on a post-ACA landscape that has altered

based

set

begin

drive

facing the U.S. health sector this year. research

investors

term

personalized

open

stream

business. phase profile The sophisticated platforms on the market, like those provided providing

by Life Technologies, are helping to drive the screening cost way down, from about $150 per test to just $12. As clinical laboratories are struggling for reimbursement dollars from the healthcare system, these molecular solutions are affording labs the opportunity to offer more of these tests while remaining profitable. moving PGx will prove to be the next big win in personalized medicine -- for patients and biotech.

benefits

company

provides

life

markets

the provision of insurance and the delivery of care.

According to HRI, 10 issues stand out as the top focus for the make health industry in the year ahead: • Price transparency is growing as purchasers – consumers and employers – are demanding and receiving more information premium February on cost and quality Charles M. Baum, M.D., Ph.D. • Employers are exploring new health insurance options through President & CEO, Mirati private exchanges diagnostic Therapeutics • New regulation aims to eliminate counterfeit medications in maintain There is a significant the drug supply chain transformation underway in the • States are turning to managed care to help contain Medicaid field of oncology, not just in terms long-term care costs of our understanding of the biology • All healthcare companies need to rethink their roles and of the disease, but also how we are significant business models in the new health economy conducting clinical trials. A trend • Healthcare companies will need to change their rules on moving we will see in clinical development innovation — embrace “fail fast” approaches in 2014 is the selection of patient populations based on defined • Social, mobile, analytics, and cloud technologies are driving abnormalities that make their tumors highly responsive to information new health industry business models nges genetic good drugs that potently inhibit those genetic alterations.

This “precision available • Corporate venture capital is picking up the slack as traditional sector medicine” approach, like we are pursuing at Mirati, started when I venture funding slows for pharmaceutical start-ups was working at Pfizer on the development of Xalkori, one of the first helpjob market • Technology is redefining the healthcare drugs approved with a companion genetic diagnostic, and is now sharing • Drugmakers must rethink their clinical trial research methods, becoming main stream. For example, a coalition of government non embracing alternative approaches pharmaceutical agencies, pharmaceutical companies, and a non-government defined seeing tailored organization have launched the “Master Protocol” study, a phase II and phase III trial to evaluate multiple drugs, assigning patients “A trend we will see in clinic al development to therapy based on their specific tumor genetic profile. in 2014 is the selection of patient The benefits of the precision medicine approach are multiple: those populations based on defined genetic targeting specific patient populations with distinct genetic profiles is much more efficient, allows for smaller studies involving only abnormalities that make their tumors 150-200 patients, and provides a definitive answer much sooner highly responsive to drugs that potently as to whether or not the drug works. Most importantly, this products inhibit those genetic alterations.” approach allows for a treatment that is tailored to each individual patient, resulting in a greater benefit and generally fewer side — CHARLES M. BAUM, M.D., Ph.D. ways pricing effects for each patient. This is a profound step forward in the oncology space, where in the past patients were subjected to drugs price largest with considerable toxicity without much predictability of response.

Michael Brown still

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether saw window health trying passion ahead

therapy

technologies

nds

quality

se

real energy

funding

esearch

office

come

capital clinical

products use find

part

rest

government continue

allows given

open

precision past space

treat

impact

over

first

William Molloie Partner, PricewaterhouseCoopers LLP Implementation of the Affordable Care Act (ACA) is only one of the factors forcing a rapid reshaping of the $2.8 trillion U.S. healthcare industry in 2014 according to PwC’s Health Research Institute (HRI). In its annual report on the Top Health Industry Issues for 2014, PwC’s HRI identifies the top 10 issues

pipeline

see

issues

take

now many

business

time

one answer

energy

greater

close

stage

trend

hope

world change

costs

IPO care

making

top remain

specific resources

life easy

Partner, Stradling Yocca Carlson & Rauth The IPO window flew wide open for life science companies in 2013, allowing San Diego life science companies to tap public markets in a meaningful way for the first time in years. Seven San Diego companies went public in 2013 year – all of them in the life sciences sector.

That’s up from one life science IPO for San Diego companies in 2012. The amounts raised in San Diego life science IPOs in 2013

Biocom LifeLines Spring 2014

7

patients

more successful

robust

medical

deal

including underway

using Cover Story

close

system

healthcare

low required

identify

event

high

jobs

data

little

example

science San Diego life science sequence

company

provides

begin

totaled approximately $465 million, with Tandem Diabetes raise of $138 million being the largest.

Many San Diego companies have taken steps to go public in “thepersonalized future is clearly in biotech and annual planning 2014, including Biocept, Celladon, Vital Therapies, and Auspex, drive biologics with regard to big pharma R&D” all of which filed S-1s with the SEC in 2013. Also, with the JOBS stream — JOE PANETTA Act’s allowance of confidential statements, there may phase registration profile research be several more San Diego life science company IPOs already consumers providing many situation underway not yet known to the public.

The degree to which the public market window for this sector initial Joe Panetta will remain open in 2014 depends largely on the performance of President and CEO, Biocom these newly public companies. In San Diego, life science firms make After years of testing the mood at JP that went public in 2013 posted mixed results. Shares of four of moving Morgan - was last year good, was last the seven companies, Tandem Diabetes, Fate Therapeutics, Ambit year bad, will this year be good or bad, Biosciences and Receptos are trading above their initial offering premium February will the IPO window stay open or will it price. Shares of three companies are trading below their initial close – my take away this time was that offering price. we’re moving toward greater stability diagnostic Shawn Pynes in the healthcare markets, and that’s a maintain Director of Employee Benefits, Barney positive thing. Healthcare as an overall & Barney market was up 60% last year.

Starting January 1, 2014, the major So, my first takeaway on the future from JP Morgan was, if portions of the Affordable Care Act (ACA) Obamacare is so bad wouldn’t the opposite be happening? So went into effect. Now, businesses with setting aside health insurance politics, pharma and healthcare significant 50 or more full-time employees need to providers are realizing is that we’ll have more insured individuals moving start executing a strategy to address the under much more comprehensive requirements for healthcare unprecedented operational and financial plans, with pre-existing conditions included. Add to that the drive challenges posed by the new law. to bring costs down information for providers and the impact of personalized good nges To get out in front of the changes and stay afloat in the competitive medicine – diagnostics, digital health products, scanning available life science industry, employers need to do the following: equipment, etc.—the importance of these sectors comes into playsector • Model the anticipated health care costs to understand the as well. help financial hit you may face.

Calculating all of the costs, sharing My second takeaway was that the future is clearly in biotech including the less obvious ones, is critical to having a and biologics with regard to big pharma R&D. In fact, one point non comprehensive understanding of the financial implications. pharmaceutical that made an impression on me was that this year for the first defined • Determine the best approach to providing health benefits tailored time, more than half of the products in development by big pharmaseeing based on your expense structure and needs. Will your will be biologics. We are already experiencing the benefits of this organization “Pay” or “Play” beginning in 2015? Life movement in San Diego, with acquisitions and partnerships by Science employers need to understand the impact their GSK, AstraZeneca and Cubist resultingthose in the establishment of strategy could take on attracting and retaining employees. their continued presence here as a result. As for the question of • Decide whether a defined contribution plan is the best whether the IPO window will remain open or will close, that is no way to proceed, including whether to participate in an longer a matter of whether biotech is “in favor”. For the foreseeable insurance exchange. This method re-engages employees in products future it is because the need will be there. the economics of health care by encouraging them to shop for benefits just like any other product.

The ACA represents the most sweeping changes to benefits ways pricing since the passage of Medicare. Preparing for the big challenges ahead will set you apart from competition and ensureprice long-term largest still sustainability.

working

benefits

right

critical

investors

term

big

open

based

set

drive

need

life

markets

2014 market partners

large

effects

best think become even ideas start outcomes

field

many

ether passion window health trying saw ahead

therapy

technologies

nds

quality

se

real energy

funding

research

come

capital clinical rest

office

products use find

8

part

Biocom LifeLines Spring 2014

government continue

allows given

open

impact

over

first

precision

treat

pipeline

see

issues

past space

take

now many

business

time

one answer

energy

greater

close

stage

trend

hope

world change

costs

IPO care

making

top remain

life

specialabout is

what’s

specific resources

sense of san diego

easy

community

the

“BioMed Realty is a trusted partner to Regulus - their entrepreneurial spirit and focus on supporting the life science industry are key drivers of growth to us and the San Diego community.”

— Kleanthis G. Xanthopoulos, Ph. D. President & Chief Executive Officer, Regulus Therapeutics

discover true partnership For more information contact Tracy Murphy at 858 207 5931

biomedrealty.com

@biomedrealty

Public Policy

By Jimmy Jackson, Vice President of Public Policy, Biocom

New Year Brings New Policy Challenges for Biocom Looking back, 2013 was a year of great change and accomplishment for the Biocom public policy team. First, we opened a full time Washington D.C. office. Within 11 months, our lobbyist helped develop federal legislation that gave biorenewables companies access to funding through the Biorefinery Assistance Program. We also coordinated a letter, signed by 30 regional life science associations, which made the sequestration of FDA funding more relevant to an overwhelming majority of Congress and their constituents.

On the state level, Biocom was a key player in helping Governor Jerry Brown pass his economic development proposal. The legislation included a state sales tax exemption for equipment used in life science manufacturing, as well as R&D, one of the only industries to get an exemption on R&D equipment. Biocom also stopped all state legislation categorized as “priority oppose.”

Many of you were able to meet Governor Brown in person as he joined us at the 2013 Biocom Annual Dinner in November.

In the final days of 2013, the Biocom board of directors voted unanimously (among those casting a vote) to endorse Councilmember Kevin Faulconer’s candidacy for Mayor of the City of San Diego. Mr. Faulconer has been a great friend and advocate for the life science industry in his time on the city council.

The life science industry spends most of its time looking forward, not back. This year, Biocom, with report partner PWC, will once again distribute its survey on the relationship between the industry and the FDA. We hope you will take the time to complete it so we have the highest quality data to take to the agency and policymakers as they begin looking at what worked in the user fee authorizations of 2012 and what needs to be addressed in the next round of user fee negotiations.

This year will also carry many challenges. As an election year, most observers do not expect a great deal of substantive new policy work to come out of Washington D.C. But as budget writers continue to look for sources of revenue to pay for federal programs, the life science industry is always at risk.

The Affordable Care Act will continue to roll out, likely with both opportunities and obstacles for Biocom member companies.

The FDA will also continue to implement the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), and continue to issue new guidances. Unfortunately, there are those who are working to erode intellectual property protections for innovators, even after the passage of the America Invents Act in 2011. Your Biocom Washington D.C. lobbyist will continue to

10

Biocom LifeLines Spring 2014

engage on these and many other issues.

On the state level, the day-to-day implementation of the Affordable Care Act will be a key issue, especially as so many states look to California as a leader in managed care implementation.

Coverage and access to appropriate therapeutic options will be paramount. Several local governments around the country have enacted, or are considering, prescription drug and combination product take-back programs, mandating that the pharmaceutical/ biotherapeutic industry bear the entire cost for these programs.

Preventing a labyrinth of different programs will be a priority.

At the local level, Biocom is working with many other stakeholders to repeal the massive increase in City of San Diego affordable housing fees charged to developers and landlords, as well as engaging with local regulatory agencies as their proposals affect the industry.

You can keep up with these subjects and all other policy issues being worked on by Biocom by going to the revamped Biocom policy section at www.Biocom.org/public_policy.

Jimmy Jackson is the Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

MEMBERS IN ACTION

BREAKFAST MEETING: Joe Panetta of

Biocom, Ken Baldwin of Ferguson Pape Baldwin Architects and Supervisor Dave Roberts; Michele Yelmene of Pharmalink Consulting, EJ Brandreth of Ajinomoto Althea and John F. Wood of Arena Pharmaceuticals, Inc.

BREAKFAST MEETING

Biocom LifeLines Spring 2014

11

MEMBERS IN ACTION

ANNUAL CELEBRATION OF LIFE DINNER Photos : JT MacMillan Photography

ANNUAL CELEBRATION OF LIFE DINNER. Clockwise from left: California Governor Jerry Brown; Heidi Chokeir of Canale Communications, Joe Panetta of Biocom and

Cammy Duong of Canale Communications; Kareem Dossa of VWR toasting to the success of the life sciences industry in 2013; Keynote Speaker Jill Bolte Taylor; The Biocom Team: Michelle Wright, Katelyn Doyle, Jennifer Landress, Ashleigh Berry, Jane Zeyak and Heather Ramsay; Chuck Cashion, Paulina Chatfield and Don Ripley of Conatus Pharmaceuticals.

12

Biocom LifeLines Spring 2014

EVENTS

By Ashleigh Berry, Associate Manager of Events, Biocom

Ten Reasons You Should Attend an Event It is easy to become swamped by day-to-day tasks, making it difficult to escape from the office for a few hours, let alone an entire day, for a business event or conference. Still, the take-home can be tremendously valuable. Events and conferences can be your resource for success, both personally and professionally. Here are my top 10 reasons you should attend some of Biocom’s events and conferences this year.

1. Networking: Social media outlets, while extremely beneficial in this era of online communication, make it way too easy to neglect actual face time. Attending a business event encourages you to interact with like-minded individuals within the industry and get talking. Biocom events help individuals create an extensive network of fellow professionals in the life science industry. To ensure valuable networking time, Biocom hosts quarterly breakfast meetings that offer a dedicated hour of networking before the panel discussion.

2. Learning: This industry is constantly growing and changing.

Attending business events helps keep you up-to-date on the latest trends. Not only does learning about the industry enhance your skill set, it also allows you stay in contact with others. Biocom advances your knowledge by offering programs on the unique challenges faced by life science companies.

3. Events can be fun!: Not every event has to be all work and no play. Corporate events can be fun as well. Evening events and full-day conferences typically end with a reception, which includes food and drinks. Biocom members receive complimentary drink tickets at these networking forums. This atmosphere can make networking much more approachable. Furthermore, Biocom often includes themes and added elements at our casual receptions to excite your interest. Biocom is currently in our 4th year of hosting an evening networking gala that includes whisky, tequila and wine tastings, along with a professional cigar roller. The cigar is yours to keep.

4. Hear from Industry Experts: Event attendees not only have the opportunity to learn from industry experts, but can also interact with them directly following their panels. Sitting in on the panel sessions also gives you the opportunity to ask these industry leaders questions about the panel topic. Every panel has a Q&A portion, during which we open the floor to all guests. Questions from the audience are invaluable, as they provide opportunities to learn from your peers.

5. Find inspiration: Don’t get caught up in the same day-today work routine and lose focus. Networking and interacting with others is a great way to bounce fresh ideas off each other and regain that inspiration. You will leave with handouts and notes,

new resources and hopefully new perspectives.

6. Increase your visibility: Attending an event increases visibility for both you and your company. Each time you share your business card, you are creating new contacts that can be valuable for both your personal and professional growth.

7. Discover new opportunities: Attending business events is a great way to market yourself if you are trying to get hired within the industry or looking to attract top talent on behalf of your organization. Events are a wonderful tool to connect and evaluate new opportunities.

8. Stay competitive: More than likely, your competitors are attending the same events you are. Speak with these companies.

Observe how other attendees are responding to them. This helps you observe firsthand what their strengths and weaknesses are and allows you to gain a competitive edge.

9. Experience new venues: Attending an event is a fun way to discover new restaurants and venues in your city. Allow Biocom to introduce you to the newest locations and indulge in gourmet food and beverages. Typically, event planners have access to unique locations that you might not be able to experience otherwise. Last summer, Biocom hosted an evening reception at the membersonly University Club that overlooks downtown San Diego. Biocom has also hosted multiple evening receptions at the Evans Garage, an antique and classic car museum that is closed to the general public. This year, you can expect more exciting receptions at new or specialized venues.

10. High-caliber speakers: Attending larger conferences and events gives you an opportunity to hear from celebrities and highcaliber community speakers you might not hear otherwise. In the past, Biocom has hosted Governor Jerry Brown, as well as famous TED speakers Jill Bolte-Taylor, Montel Williams, John Crowley and Bob Saget, to name a few.

With numerous events and industry conferences to choose from, it can be overwhelming and time-consuming to attend them all.

It is not necessary to attend every event that comes your way, but attending several throughout the year can help you immensely on your path to professional growth.

Ashleigh is the Associate Manager of Events for Biocom and is in charge of organizing and marketing Biocom events.

Biocom LifeLines Spring 2014

13

Premier Supplier in the Purchasing Group

Since 2002, Prudential Cleanroom Services and Prudential Overall Supply continues to provide BIOCOM Members reusable textile products and services for rental, lease and direct purchase programs.

ISO 9001:2008 CERTIFIED

TRUSTED BY LEADERS A DIVISION OF PRUDENTIAL OVERALL SUPPLY WWW.PRUDENTIALUNIFORMS.COM 800-767-5536

PRU D EN T I A L I S DEDI CATED TO SU STA IN A BIL IT Y

Premier Supplier in the Purchasing Group

PRUDENTIAL IS...

THE RIGHT

CHOICE

CAREER & CASUAL

FACILITY PRODUCTS

PROTECTIVE APPAREL

MEDICAL APPAREL

CULINARY APPAREL

NAPKINS

TOWELS

MOPS & BUCKETS

RESTROOM PRODUCTS

CLEANROOM

MATS

800-767-5536

WWW.PRUDENTIALUNIFORMS.COM

Guest

By Mandy Jackson, West Coast Editor, SCRIP Intelligence

San Diego Public Companies to Watch in 2014 Legacy firms and recent IPOs face important milestones San Diego’s biotechnology cluster will be a newsworthy group in 2014, with several companies on track to achieve research and regulatory milestones for drug candidates in their pipelines.

While the region lost some long-time biotech industry members to acquisitive companies in 2013, stock market gains and initial public offerings (IPOs) gave other businesses the resources they needed to grow.

Cubist Pharmaceuticals bought the antibiotic developers Trius Therapeutics and Optimer Pharmaceuticals for more than $1.2 billion plus future milestone fees. But while decision-making responsibilities for Trius and Optimer have shifted from San Diego to Lexington, Mass., many local biotech firms showed their staying power in 2013.

Antisense drug developer Isis Pharmaceuticals strengthened its presence in Carlsbad with a 268 percent increase in its stock price between January and December, bringing its market capitalization to $5.6 billion as of January 21. The company had more than $625 million in cash at the end of 2013 to support its development pipeline, which includes five drug candidates that could be submitted for U.S. Food and Drug Administration (FDA) approval by 2018.

Isis’s partner Genzyme launched the homozygous familial cholesterolemia drug Kynamro (mipomersen sodium) in 2013. Isis also reported positive data from 10 clinical trials for five different antisense drugs, initiated one new Phase III and five new Phase II trials and added four new drug candidates to its pipeline.

“Those successes set the stage for even more success in 2014 and more to follow,” Isis chairman and CEO Stanley Crooke said during his presentation on January 13 at the 32nd Annual JP Morgan Healthcare Conference in San Francisco.

The high-profile JP Morgan conference has become the annual kickoff event for the life science industry. This year’s conference was the first time Helen Torley spoke at a major investor event as the new president and CEO of Halozyme Therapeutics, another mainstay San Diego biotech company.

Dr. Torley said 2014 will mark a transformation for Halozyme as it shifts from enabling subcutaneous versions of intravenous medicines on behalf of its partners to producing novel therapeutics for the company’s own portfolio.

“No longer the royalty platform story, we are transforming into

16

Biocom LifeLines Spring 2014

a products company as well with a diversified pipeline,” she said on January 16.

Halozyme will announce clinical trial enrollment progress for the anti-cancer agent PEGPH20 during the second half of 2014. The company also plans to report top-line data during the first quarter for Hylenex, which treats type 1 diabetes, and from a Phase II cellulite study with HTI-501. In terms of partnered programs, the FDA should make an approval decision for Baxter’s HyQvia by mid2014. Also, a European Medicines Agency (EMA) committee is expected to make a recommendation for Roche’s subcutaneous MabThera this year.

Orexigen Therapeutics has marketing applications pending in the U.S. and Europe. The San Diego-based company should have an FDA decision by June 20, and an EMA recommendation by the fourth quarter of 2014, for its obesity drug Contrave (naltrexone SR/bupropion SR).

Orexigen’s prescription weight loss therapeutic will compete with Belviq (lorcaserin) from San Diego-based Arena Pharmaceuticals.

Arena’s partner Eisai launched Belviq in the U.S. on June 11 and Vivus of Mountain View, California began selling its obesity drug Qsymia (phentermine and topiramate) in September 2012.

The competition between the obesity drug developers garnered a lot of attention in 2013, and that’s not likely to change in 2014, as Orexigen nears U.S. and European approvals.

But the biggest news in biotech last year – in San Diego and elsewhere – was the open window for IPOs, which doesn’t look like it will close anytime soon.

Six San Diego-based companies were among the 38 drug developers that completed an IPO in the U.S. in 2013: Receptos, Ambit Biosciences, Conatus Pharmaceuticals, Sophiris Bio, Evoke Pharma and Fate Therapeutics.

Ambit will start a Phase III clinical trial for the acute myeloid leukemia drug quizartinib in early 2014. Sophiris will complete patient enrollment for the first Phase III trial for PRX032, to treat benign prostatic hyperplasia (BPH), during the second half of the year.

Evoke also has plans for a Phase III clinical trial to test EVK-001 (intranasal metoclopramide) to manage diabetic gastroparesis. An earlier-stage company, Fate expects to restart a Phase II trial in adult hematologic malignancies in the first half of 2014 for its

Guest

hematopoietic stem cell therapy ProHema.

Conatus intends to announce Phase IIb clinical trial results for emricasan, to treat acute-on-chronic liver failure (ACLF), in the first half of 2014. The company will also initiate a Phase II trial for nonalcoholic steatohepatitis (NASH) and Phase IIb studies for chronic liver failure (CLF) and hepatitis C virus – post-liver transplant (HCV-POLT).

Finally, Receptos recently began the Phase III portion of the Phase II/III RADIANCE clinical trial for RPC1063, which treats relapsing multiple sclerosis (RMS). The company expects to start a second Phase III RMS trial after it reports Phase II RADIANCE data in mid-2014.

Annual Open House And Purchasing Group Supplier Showcase Wednesday, July 23rd 4-7pm Biocom Courtyard

Mandy Jackson writes about small and midsized biotech companies for the biopharma news website Scrip Intelligence.

www.biocom.org

Make Your Mark

in

BiotechnologY

Professional Science Master’s The Professional Science Masters in Biotechnology is the premier degree in San Diego. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/degreeprograms/psmlifelines/index.html

HURRY! Fall 2014 Start

ApplY TodAY

Science Festival

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

BE THERE

San Diego Festival of Science & Engineering, March 22 More than 25,000 San Diegans are expected to attend the San Diego Festival of Science & Engineering (SDFSE) on Saturday, March 22 at PETCO Park. Join us there for more than 100 different hands-on activities that will excite your mind about science, technology, engineering and mathematics (STEM).

This event is geared towards children kindergarten through college but is open to anyone who wants to learn about STEM and how this industry is thriving in our own backyards. Come with your family and friends and open them up to this world and the dedication that drives our industry. The innovations of the future are being created right beside us every day. All it takes is one spark to ignite a child’s passion.

Some of those future innovators have already showed their stuff by winning a Bright Idea Society award. This program encourages schools to submit ideas for STEM-related, project-based learning.

Winners are chosen from three categories: elementary, middle and high school. Each school receives a $500 stipend to bring their project to fruition, booth space at the Festival to present their activity to the community and transportation to and from the event.

This annual education program is sponsored by the Kimmich Foundation, and transportation this year is being provided by the San Diego Financial Literacy Center.

SDFSE is free and open to the public thanks to our many wonderful sponsors. Some of this year’s top contributors include: ABC10 /10News & Azteca San Diego 15, Biocom, Cox Media, Jammin’ Z90 and Magic 92.5, Life Technologies, San Diego Padres, Time Warner Cable and ViaSat, Inc. In addition, we are very excited to have three educational partners on board: The Reuben H. Fleet Science Center, The San Diego County Office of Education and University of California, San Diego. Their support, along with a host of additional sponsors, helps make this a free community event.

If you can’t make it to PETCO on the 22nd, not to worry, there are still plenty of opportunities to participate in the Festival with its week of activities throughout the county.

• Visit Taylor Guitars, where guests will tour the facility and learn the steps of guitar construction from wood selection to final assembly.

• Check out the Escondido Police Department, which will expose students to the Crime Lab and Traffic Division and how they use math and physics to complete investigations. They will showcase equipment to gather data and conduct experiments. Officers and

18

Biocom LifeLines Spring 2014

SAVE T

HE

DATE

MARCH 201 4

MA RC H

15TH-21ST Science, Technology, Engineerin

g & Math

STEM Events

Throughout San Diego County

www.sdsc

p

MA RC H

22ND

i

EXPO DAY at PETCO Park

iencefestiv al.com

E FRETIONAL CA

EDU

e

FUN

laboratory technicians will explain how scientific principles are used daily to solve crimes and determine how traffic collisions occurred.

• Have little ones? Visit The New Children’s Museum (NCM), where they are experimenting with food’s many possibilities in their latest exhibition, Feast: The Art of Playing With Your Food.

You’ll be invited to play inside “Mold” - the museum’s one-of-akind building block environment made entirely of fungi. Children will have the opportunity to explore different mushroom species by creating mushroom stamp prints in a special workshop in the NCM Art Studio.

For a full listing of events, to see what’s happening in your part of town, and more information on Festival Day, please visit www. sdsciencefestival.com. We look forward to seeing you and your family during Festival Week.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

We have advanced the art of HIPAA, FDA & Unified Compliance to a Science

Biocom Institute

By Liisa Bozinovic, Executive Director, Biocom Institute

Life Science Summer Institute Celebrates 10th Anniversary of Developing a Workforce Pipeline The San Diego Workforce Partnership, in collaboration with Biocom and the Southern California Biotechnology Center at Miramar College, created the Life Sciences Summer Institute (LSSI) to strengthen science and math education and prepare people for careers in the life sciences.

LSSI programs target two populations, high school students and high school teachers. The goal is to encourage youth to explore careers in science, technology, engineering and math (STEM).

LSSI was originally piloted with a Department of Labor grant.

Today, it is fully supported and funded by the biotech industry.

This year, LSSI celebrates its 10-year anniversary.

LSSI provides high school students with summer internships, including a one-week, pre-internship “boot camp” to prepare them for hands-on research experience. Since 2005, the program has trained and placed more than 366 students in summer research internships, working alongside Nobel Prize-winning scientists, participating in scientific talks and conducting hands-on research.

Students earn college credit for their boot camp course, receive college prep units from the University of California San Diego Extension and create a scientific poster of their work. The program has expanded to run two concurrent boot camp sessions at Grossmont College and Miramar College and maintains strong partnerships with both the Salk Institute and the Scripps Research Institute. Students from all areas of San Diego apply to be part of this highly competitive program. LSSI receives more than 300 applications per year for only 35 to 40 positions.

Jake Maskiewicz credits LSSI for his major successes. During the summer of 2010, Maskiewicz interned in a computational biology lab at the Salk Institute and has remained there ever since.

Lesly Basave, a student from a small charter school, faced many challenges including working late nights with her parents cleaning office buildings. Science was never a career option for her. However, after interning at The Scripps Research Institute she was offered part-time employment and went on to pursue a biology major. LSSI provides youth with classroom and experiential opportunities that empower them to broaden their career horizons.

In the 12-day professional development program, science teachers receive training through the Amgen Biotech Experience (ABE) curriculum and exposure to companies, such as Conatus, Genentech, Illumina, Life Technologies, Pfizer, Pharmatek, Pfenex and Sapphire Energy. By the end of the course, teachers have the skills, equipment, and supplies necessary to implement the

20

Biocom LifeLines Spring 2014

curriculum in their classroom. Teachers also receive first-hand knowledge about the job market, as well as the hard and soft skills needed to be successful in the biotech workplace.

The program has trained more than 180 science teachers across San Diego, Riverside and Orange Counties, impacting more than 37,000 students and sparking student excitement at scientific discovery.

The program has extended its services to Riverside County, providing materials and lab equipment for teachers. Through Miramar College’s Biotechnology program, teachers can articulate their high school biotechnology courses. More than 780 students have passed the credit-by-exam process, eliminating duplication of learning in post-secondary education.

Today, LSSI has expanded its training to include a two-week bridge program. The Introductory Life Sciences Experience (ILSE) was first piloted in 2009 to provide students experiencing economic and social barriers with direct exposure to the life sciences industry through hands-on laboratory training, interactions with scientists and visits to biotechnology sites across San Diego.

The program has trained more than 70 students and has ignited their interest in STEM-related opportunities. Students taking part in these programs have received scholarships, have been accepted into Ivy League universities and have become gainfully employed in science-related fields. LSSI has been a vehicle to help decrease the region’s gap in STEM employment.

The program’s application period is currently open and information can be viewed at www.matsc.org. Become part of the LSSI team by hosting teachers, hiring an intern or providing student sponsorships.

For more information, contact Erika Aranguré, San Diego Workforce Partnership, at Erika@workforce.org. This is your opportunity to help promote STEM education by supporting a wellestablished program with 10 years of proven success.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR initiative.

ALWAYS HELPFUL. ALWAYS RELIABLE. Every company requires help along the path to success. Finding service providers you can count on can be time-consuming and difficult. Let us help you by connecting your needs with the services of a trusted fellow Biocom member.

www.Biocomconcierge.org

Purchasing Group

By Rick Fultz, Managing Director, Biocom Purchasing Group

Our 2014 New Year’s Resolutions As we close the chapter on one of our most successful years to date, we’d like to take this opportunity to extend our heartfelt gratitude to our members for their participation in our contracts.

This participation has allowed us to attract industry-leading suppliers to our RFPs, secure stronger price concessions and bring more robust contract offerings. Your willingness to be a team player has led to unparalleled savings and services for all our members.

With last year’s appointment of our quality control specialist, we were finally able to deliver on the increased contract compliance and quality control systems that our members have requested. Together with our expanding member base of qualified professionals, we completed our first successful circuit of advisory committees for all six contract areas.

We have honed in on five major goals for 2014, and with your assistance, we expect to knock these out of the park.

1. Save You Even More Time and Money The Biocom Purchasing Group saved members more than $60 million in 2013, up from $48 million in 2012. One contributor to this increase was our partnership with Barney & Barney’s Beyond Benefits program: the first-of-its-kind health care trust that helped our members leverage the positive health risk of the life science industry. Since its inception, more than 88 members have joined, saving more than $2.3 million.

In 2014, we’re setting the aggressive goal of saving Biocom members more than $75 million. This benchmark is inspired by our members and reflects the commitment we have to you.

2. Add More of the Services You Need It is hard to believe that, with more than 40 suppliers in our savings portfolio, we still have not accounted for all your procurement needs. With last year’s introduction of new member surveys, formal feedback systems and member retention meetings, however, we were able to identify three contract areas for which we plan to conduct RFPs in 2014-2015. Be on the lookout for RFP committee invitations for mobile communications, e-procurement tools and domestic airlines. As always, please do not hesitate to contact us with suggestions at PGSupport@Biocom.org.

3. Enhance Our Communication Channels Another takeaway from our recurring advisory committee meetings is the concept of hosting bi-annual conference calls/ webinars to discuss current suppliers, prospective contract areas and the industry’s competitive landscape. The Biocom Purchasing

22

Biocom LifeLines Spring 2014

Group always operates in the best interest of our membership.

However, the possibilities are endless when we can collaborate with more than 600 member companies to address key focus areas and create plans for the future. Our first call is scheduled for May 2014, and we look forward to hearing from you.

4. Incorporate More Value-Added Benefits Last year’s introduction of our Supplier Event Series was a huge success, consolidating events for our members and forging stronger, industry-specific partnerships. We will continue to press on our suppliers to offer additional value-added services at low or no cost to you. Veolia, our endorsed waste management supplier, is starting the trend this summer with their complimentary RCRA & DOT 2-day training and certification program. For all Biocom members who work at or oversee hazardous waste operations, we strongly encourage you to take advantage of these free resources and industry-mandated certifications.

5. Expand the Biocom Travel Network The Biocom Travel Network is a full-service program, offering members exclusive access to competitive, high-volume discounts to destination hotels, travel booking tools and air and ground transportation programs, regardless of their company size or travel frequency. We also have a heavily discounted contract lined up with Concur, the travel and expense management supplier of choice with many member companies, offering integrated solutions for travel bookings and policy and regulatory compliance. In 2014, we plan to aggressively pursue additional hotel discounts in Boston, New York City and Washington, D.C. Our goal is to create a comprehensive travel program that strengthens business for our members in San Diego and beyond.

We thank you all for your continued support and look forward to serving your procurement needs for many years to come.

Rick oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

Silent Auction

San Diego craft brew tastings

Golf Pro Trick Shot Show

Hole in One Contests

rity a h C m Bioco

m a e n n t r u o T f G ol

21, 2014 The Santaluz Club l i r p A day n o M

Gourmet dinner

BENEFITING:

Space is limited and registration is filling up fast! Sign up today to secure your place.

www.Biocom.org

And much much more........

SPONSORED BY:

PREMIUM MEMBER SPOTLIGHTS PREMIUM MEMBERS AbbVie* Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Bioserv Corporation Biospace BP Biofuels Cadence Pharmaceuticals* California Manufacturing Technology Consulting Canale Communications Celgene COI Pharmaceuticals Conatus Pharmaceuticals Cooley County of San Bernardino Economic Development Agency Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic Janssen Research & Development Jones Day KPBS Latham & Watkins Life Technologies Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Patheon Pfizer Praxair* PwC VWR International Wilson Sonsini Goodrich & Rosati * New Members from October 2013 to January 2014

24

Biocom LifeLines Spring 2014

www.fishersci.com Name: Bill Yang Job title: Vice President Sales, West Region Favorite movie: She Wore a Yellow Ribbon Favorite book: The Complete Far Side, Volume I and II”, Gary Larson Favorite quote: “Be civil to all; sociable to many; familiar with few; friend to one; enemy to none’. Benjamin Franklin Favorite TV show: Big Bang Theory Favorite restaurant or meal: Stella Alpina Osteria (Italian) in the Bay Area Favorite city: Madrid Favorite actor/actress: John Wayne/ Diane Keaton Favorite thing to do on the weekends: Spending time with family and friends What CD can we find in your car: Toby Keith “Unleashed” Favorite hobby: Bicycling Favorite website: www.facebook.com First job: First non professional job: Paper route. First professional job: Sales representative at American Scientific Products Favorite part of your job: Building relationships with our customers, learning about their research and contributing to their discoveries and successes.

If you could have another career, what would it be: Veterinarian Why did you start working in your industry:A fascination with science at a young age. I remember sitting on the floor, encyclopedias spread all around me and being amazed at everything that had been discovered and all that was still left to be discovered.

www.gelifesciences.com Name: David Sanborn Job title: Sales Specialist Favorite movie: The Good, The Bad and The Ugly Favorite book: “1421” Favorite quote: “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” Buddha Favorite TV show: Star Trek; The Next Generation Favorite restaurant or meal: Saffron in Mission Hills Favorite city: San Diego Favorite actor/actress: Clint Eastwood Favorite thing to do on the weekends: Events and outdoor activities with my family What CD can we find in your car: John Butler Trio Favorite hobby: Working in the yard Favorite website: GE Life Sciences Favorite spot in Southern California: Torrey Pines State Beach Park First job: Research Scientist at Thomas Jefferson University Favorite part of your job: Meeting and working with scientists in southern California If you could have another career, what would it be: National Park Ranger Why did you start working in your industry: Interest in human physiology

PREMIUM MEMBER SPOTLIGHTS www.janssenlabs.com Name: Kara Bortone, PhD Job title: Head of Company Sourcing Favorite movie: Amélie Favorite book: One Thousand Splendid Suns by Khaled Hosseini Favorite quote: “Take your work seriously, but never yourself” – Margot Fonteyn Favorite TV show: 30 Rock Favorite restaurant or meal: Fish tacos Favorite city: Barcelona Favorite actor/actress: Audrey Hepburn Favorite thing to do on the weekends: Cook a big meal and enjoy it with friends and family What CD can we find in your car: London Calling – The Clash Favorite hobby: Mountain biking Favorite website: YouTube Favorite spot in Southern California: Santa Monica First job: Rollerblading Subway Sandwich Artist at the boardwalk Favorite part of your job: Meeting entrepreneurs that are dedicated to pushing the edge of what is possible If you could have another career, what would it be: Architect Why did you start working in your industry: I wanted to be at the interface of science and business and be a part of delivering life changing solutions to patients.

www.wsgr.com Name: Dan Koeppen Job title: Partner Favorite movie: Goodfellas, Something Ventured, and Toy Story 2 Favorite book: “When Pride Still Mattered : A Life Of Vince Lombardi” and “Howard B. Wigglebottom Learns to Listen” Favorite quote: “Never mistake activity for achievement” – John Wooden Favorite TV show: The Wire, Sopranos, Sons of Anarchy, Breaking Bad, House of Cards, and Jake & the Never Land Pirates Favorite restaurant or meal: O’Sullivan Bros. Brewing Co. Tasting Room & Beer Garden (coming in 2014) Favorite city: San Diego Favorite actor/actress: Ian Dale Favorite thing to do on the weekends: Play basketball and spend time with my wife and two kids.

What CD can we find in your car: Something from the 90’s like “Monster Ballads” because that’s the last time I bought a CD. Favorite hobby: Basketball, skiing, and watching the Green Bay Packers Favorite website: www.espn.com and www.jsonline.com/sports Favorite spot in Southern California: Sage Canyon Park First job: Cedarburg (WI) Department of Public Works Favorite part of your job: Being able to help entrepreneurs create valuable products and services and have successful exits.

If you could have another career, what would it be: High school basketball coach and history teacher.

Why did you start working in your industry: It was my desire to be able to have an influence in building and growing companies that create novel products and services that affect people’s lives.

BECOME A PREMIUM MEMBER TODAY With our premium membership you get increased visibility and added value to your membership. We offer our premium members maximum exposure opportunities and access to exclusive events in the life science community.

To become a premium member contact: Kira Jenkins, Director of Membership kjenkins@Biocom.org or 858.455.0300 x117

Company logo seen by 100,000 life science professionals.

Company news briefs and event announcements sent to over 360,000 people annually.

Additional discounts offered at key conferences An employee featured in LifeLines Magazine Direct access to 15,000 people through a targeted email blast.

And many more......

Biocom LifeLines Spring 2014

25

Board of Directors BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Magda Marquet, Ph.D., Ajinomoto Althea* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Theodore Schroeder, Cadence Pharmaceuticals* VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* VICE PRESIDENT – INDUSTRY: Daniel Burgess CHAIR EMERITUS: David Webb, Ph.D.* PRESIDENT & CEO: Joe Panetta, Biocom* Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Remi Brouard, M.D., Sanofi R&D West Coast Michael Brown, Stradling Yocca Carlson & Rauth Terrance J. Bruggeman, BioTork, LLC Timothy Caulfield Daryl Dorcy, AbbVie John M. Dunn Geoffrey S. Eich, Amgen Stephen Ferruolo, J.D., Ph.D., USD School of Law* M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio, Brinson Patrick Securities Gregory Frost Alan Gold, BioMed Realty Trust Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Terry Gregg, Dexcom Jason Hannon, NuVasive Richard Heyman, Ph.D., Seragon Pharmaceuticals Jim Hinrichs, CareFusion Elliot Hirshman, Ph.D., San Diego State University Matthew Hudes, Deloitte LLP Guy J. Iannuzzi, Mentus David Kabakoff, Ph.D., Sofinnova Ventures Steve Kaldor, Ph.D., Quanticel Michael Kamdar, Cellana, Inc. Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Kevin Larkin, TherOx Jacob Levin, Ph.D., UC Irvine

James Levine Jack Lief, Arena Pharmaceuticals, Inc.* Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* William Molloie, PwC Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* Brian O’Callaghan Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Gregory Reyes, M.D., Ph.D., Celgene Dan Ryan, Alexandria Real Estate Equities Camille Saltman, MD Revolution James Schaeffer, Ph.D., Merck Research Laboratories* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek Laboratories, Inc.* Martin Seidel, Ph.D., Genomics Institute of the Novartis Research Foundation Bhasker Shetty, Ph.D.,Pfizer La Jolla Larry Stambaugh* Mark Stevenson, Thermo Fisher Scientific * Scott N. Wolfe, Latham & Watkins Randall E. Woods, Sophiris Bio* LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Tina Nova, Ph.D., Genoptix, Inc. A Novartis Company Biocom Board Members-Ex-Officio: Sandra Brown, Ph.D., UCSD Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Scott Lippman, MD, Moores Cancer Center, UCSD Peter Preuss, The Preuss Foundation Jerry Sanders, San Diego Regional Chamber of Commerce *Executive Committee Member

Committee leadership Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Laboratories, Inc. Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield FDA Committee Magda Marquet, Ph.D., Ajinomoto Althea Michele Yelmene, Pharmalink Consulting

Intellectual Property and Patent Law Committee Margaret Dunbar, Sanford-Burnham Medical Research Institute Daniel Hart, Knobbe Martens Olson & Bear LLP Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals Medical Device Committee Noel Gillespie, Procopio, Cory, Hargreaves& Savitch Joleen Schultz, Rady School of Management, UCSD mHealth Committee Camille Saltman, MD Revolution

Public Policy Oversight Committee* Larry Stambaugh Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Scholarship Committee Bente Hansen, BenteHansen and Associates Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.

Biocom LifeLines Spring 2014

27

Biocom MEMBERSHIP PREMIUM

Cadence Pharmaceuticals* California Manufacturing Technology Consulting Canale Communications Celgene COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP County of San Bernardino Economic Development Agency

Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic

Janssen Research & Development Jones Day KPBS Latham & Watkins Life Technologies Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo

NuVasive Patheon Pfizer Praxair* PwC VWR International Wilson Sonsini Goodrich & Rosati

Biotechnology

BioWa Boehringer-Ingelheim Curtana Pharmaceuticals CalciMedica CannaVest Corporation CARBOGEN AMCIS Cebix Cell Applications Celladon Cellana Cell Signaling Technology* Center for Aquaculture Technologies Cibus Coda Therapeutics Conju-Probe Contract Biotics CURx Pharmaceuticals* Custopharm Dart Neuroscience Denovo Biomarkers DSM Food Specialties eFFECTOR Therapeutics Electronic BioSciences eMolecules Epeius Biotechnologies Equitech Bio Fabrus Fate Therapeutics Formex Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation* GenSignia GlaxoSmithKline Guangdong Consun Pharmaceutical Company* GWR Instruments

Halozyme Therapeutics Harbor Therapeutics Histogen Huya Bioscience International Illumina Inception Sciences Inhibrx InnoPep Innovative Cell Technologies Inovio Pharmaceuticals Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrepid Therapeutics Intrinsic LifeSciences Invetech InvivoGen IRBCo. ISIS Pharmaceuticals Jaleva Pharmaceuticals J-Oil Mills Kalyra Pharmaceuticals Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company* Ligand Pharmaceuticals Lithera Lpath Lumena Pharmaceuticals MabVax Therapeutics Mast Therapeutics MEI Pharma Meritage Pharma Monsanto Nautilus Environmental NaZura BioHealth NeuroGenetic Pharmaceuticals Nitto Denko Technical Novartis Pharmaceuticals Noven Pharmaceuticals

Novo Nordisk Nucelis Ocera Therapeutics Optimum Therapeutics Orexigen Therapeutics Otonomy Pacira Pharmaceuticals Panmira Pharmaceuticals Pathway Genomics Pfenex PharmAkea Polaris Group Polynoma PolyPeptide Group Predictive Biology Preventice PrimaPharm PrimeGen Biotech Prognosys Biosciences ProSci QED Bioscience Quanticel Pharmaceuticals Receptos Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Ridgeline Engineering Roche Applied Science* RQX Pharmaceuticals RuiYi Samumed Sanguine BioSciences Sanofi Scripps Laboratories Senju USA Senomyx SentĂŠ Seragon Pharmaceuticals

SG Biofuels Shin Poong Pharmaceutical Company Sirenas Marine Discovery Solstice Biologics SoluLink Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Stemedica Cell Technologies Sunovion Pharmaceuticals Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories Tenova Pharmaceuticals Thesan Pharmaceuticals Tocagen Tonbo Biosciences Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Trius Therapeutics UCB US Specialty Labs* Vala Sciences Vantari Genetics Vaxiion Therapeutics Verdezyne Verenium Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies Zensun USA Zogenix

CRO

Behavioral Pharma Bend Research BioAtla CalChem Synthesis Cato Research Charles River Laboratories ChemDiv Concortis Biosystems Cytelligen Davos Chemical Eastern Clinical Trials EastHorn Clinical Services Epistem eStudySite Exon BioSystems

Explora BioLabs GENEWIZ GRAM Laboratories Hamari Chemical San Diego Research Center Huntingdon Life Sciences Integrium Clinical Research IriSys JadeBio MedinCell MicroConstants Molecular Response MPI Research Neuroservice* OOxesis Biotech

PacificGMP PharPoint Research* Pharmatek Laboratories PPD Prescos Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Reveal Biosciences Rho Robarts Clinical Trials SAFC Pharma SeqWright Genomic Services

Sherpa Clinical Packaging Stemgent SynteractHCR Therapeutics, Inc. Tioga Research Toxikon Triligent International Ultimate Labs Verum.us Virapur Wax-It Histology Services Zyagen

AbbVie* Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Bioserv Corporation Biospace BP Biofuels

Abgent Abide Therapeutics Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Afraxis Aires Pharmaceuticals Allylix AM Chemicals AMBRX Amgen Amicrobe Amplyx Pharmaceuticals Amylin Pharmaceuticals AnaptysBio AndroScience Apricus Biosciences Arcturus Therapeutics Ardea Biosciences Arrayomics Astellas Pharma aTyr Pharma Auspex Pharmaceuticals Avantgen Avelas Aviva Biosciences Bachem Americas BioLegend Biomatrica Biomyx BioNano Genomics Bionomics Bio Options BioSpyder Technologies* BioTork

Abbiotec Absorption Systems Accelagen Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Alliance Protein Laboratories Ambit Biosciences American Peptide Company AMRI Annova Chem ARIANNE

28

Biocom LifeLines Spring 2014

Medic al Device & Diagnostic

Cell Idx CeloNova BioSciences Celula Cliniqa Corporation ClinMet Compellon CRISI Medical Systems Critical Diagnostics CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Ellipse Technologies Enigma Diagnostics Entra Health Systems Epic Sciences Epitope Diagnostics

Fallbrook Engineering FemCap Fortimedix USA Freedom Meditech GenWay Biotech Glaukos Corporation Glysens Hitachi Chemical Research Center Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inceptus Medical INOVA Diagnostics Interventional Spine InVision Biomedical Group Invivoscribe Technologies Ionian Technologies Ivantis

Ivera Medical KFx Medical Liferiver MARDX Diagnostics MD Revolution Med Systems Micell Technologies Millennium Laboratories Nano Imaging Services OncoSec Medical Organovo Prometheus Laboratories Qualigen Quantum Design Quidel ReShape Medical REVA Medical Reverse Medical ReVision Optics

Ridge Diagnostics Roka Bioscience Sequenom Shire Sienna Labs Sirigen Sonendo* SpectraScience Suneva Medical Tandem Diabetes Targeson Tensys Medical TherOx Tristan Technologies Trovagene Uptake Medical Valor Medical VertiFlex Yulex

Key Provider

Biotech Vending BioTix Blue Sky Broadcast Bootstrap Incubation Brinson Patrick Securities Caliber Associates California Commercial Security Campbell Alliance Canteen Vending Services CB Richard Ellis Cenduit China Business Partners Chubb Group of Insurance Companies Clinigen Healthcare Compete Consulting Controlled Contamination Services Cox Business* Cymer Domain Associates EBD Group Elsevier Enterey EquipNet Euretos Ferguson Pape Baldwin Architects

Fish & Richardson Fisher & Phillips Forward Ventures French Biobeach* Frequentz* Gensler Good & Roberts Grande Colonial Grant Thornton HCP Life Science Estates Hyatt Regency La Jolla at Aventine Innovative Commercial Environments Innovative Lease Services J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle* KBM Facility Solutions Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Legacy Partners Commercial Levementum LG Technology Center of America Managed Solution Mayer Hoffman McCann

McKenna Long & Aldridge Mission3 Morgan, Lewis & Bockius Morrison & Foerster Occupational Services Office Depot OfficeMax / Workplace Interiors Ogletree, Deakins, Nash, Smoak & Stewart OmniComm Systems Oxford Finance Pegasus Cleanroom Services Pharmalink Consulting PR Newswire Prevost Construction Project Management Advisors Prudential Cleanroom Services Relocation Coordinates Retirement DNA San Diego World Trade Center Sanford Rose AssociatesÂŽ - Toft Group Sartorius SecureDocs Scient Federal Credit Union* Sharp Business Systems

Sheppard Mullin Richter & Hampton Shred San Diego Silicon Valley Bank SLM Group Sofinnova Ventures Sonceboz Corporation Square 1 Bank S Squared Executive Search* Stradling Yocca Carlson & Rauth Studley Sughrue Mion Technical Safety Services The Business Cleaning Company The HealthEd Group The Sandler Group Thomas, Mcnerney & Partners T-Mobile USA United Parcel Service (UPS) Urban Contracting VDP Direct Veolia Virgin America Vision33

Human BioMolecular Research Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute Kaiser Permanente* KOTRA - Los Angeles La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute MiraCosta College Biotech Program Mt. San Jacinto College PhRMA Point Loma Nazarene University

Quebec Government Rady School Of Management, UCSD Salk Institute For Biological Studies San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego Employers Association* San Diego Natural History Museum San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership San Diego Zoo Global Sanford-Burnham Medical Research Institute

Scottish Development International Scripps Health Scripps Research Institute Swedish American Chamber Of Commerce San Diego The BioIndustry Association The Lowy Medical Research Institute (LMRI) Torrey Pines Institute for Molecular Studies UC San Diego Extension UCI’s Office of Research UCSD, Department of Bioengineering UCSD, External Relations Office UCSD School of Medicine UCSD, Technology Transfer Office UK Trade & Investment University of San Diego

Individual

Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx America Diagnostics Applied Proteomics Astute Medical Aviir BeneChill Biocept BioDx Biological Dynamics bioTheranostics Breathe Technologies Bruin Biometrics CareFusion

Airgas Barney & Barney Cushman & Wakefield Oracle Health Sciences Procopio, Cory, Hargreaves & Savitch Qualcomm San Diego Gas & Electric

Provider

2Connect Accelrys AIS (American Internet Services) AlphaGraphics of La Jolla AMN Healthcare Assay Depot Austin Commercial Beckloff Associates Bente Hansen & Associates Bingham McCutchen Bionest Partners Biosources BioSurplus Biotech Primer

Non-Profit

American Cancer Society, Border Sierra Region American Red Cross - San Diego CA Institute for Regenerative Medicine Calibr California Baptist University, College of Engineering California State University, San Marcos City Of Murietta CONNECT Consulate Of Canada CSU,CSUPERB Program Escondido Union High School District* Foundation For Personal Financial Education

Antoinette Azevedo Bernard King Carol Gallagher* Elliot Parks Gary Friedman John Kavanagh Julie Ames Larry Stambaugh Peter Preuss Richard Ledford

* New Members from October 2013 to January 2014

Biocom LifeLines Spring 2014

29

Prsrt Std U.S. Postage PAID Permit #2325 San Diego, CA

4510 Executive Drive, Plaza One San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to Katelyn Doyle at kdoyle@Biocom.org.

3-DAY EVENT

Mammalian Fermentation Workshop April 30-May 2, 2014 | 8:00 a.m. – 5:00 p.m. | UC San Diego Campus, La Jolla, CA This 3-day workshop, developed in partnership between UC San Diego’s Center for Continuing Education in Biosciences (CCE|BIO) and UC San Diego Extension, is designed to provide participants with a deeper understanding of the performance of mammalian cell culture operations throughout the product and process life cycle from process development to full scale manufacturing under current Good Manufacturing Practices. This workshop combines practical knowledge with case studies to provide participants with the ability to thoroughly analyze experimental cell culture results.

• Learn about the history of mammalian cell biotechnology and challenges faced • Gain an overview of the manufacturing process • Explore key issues and tools used in industrial cell culture operations • Develop a deeper understanding of technology transfer and scale-up

SPEAKERS: MICHAEL DAVID, PH.D. Professor Molecular Biology UC San Diego MICHAEL FINO, M.ENG. Professor Bioprocess Technology MiraCosta College MICHAEL POHLSCHEIDT, PH.D. Director Manufacturing Operations Genentech ERIC M. FALLON, PH.D. Director Technology Genentech

• Analyze experimental cell culture results using proper statistical analysis

For more information and to register: extension.ucsd.edu/lifesciences | (858) 534-9353 | unexbio@ucsd.edu Group Discounts Available!

Genentech Site Visit Included